Abstract:Abstract Angelman syndrome (AS) is a rare neurodevelopmental disorder characterized by developmental delay, impaired communication, motor deficits and ataxia, intellectual disabilities, microcephaly, and seizures. The genetic cause of AS is the loss of expression of UBE3A (ubiquitin protein ligase E6-AP) in the brain, typically due to a deletion of the maternal 15q11-q13 region. Previous studies have been performed using a mouse model with a deletion of a single exon of Ube3a . Since three splice variants of Ube3a exist, this has led to a lack of consistent reports and the theory that perhaps not all mouse studies were assessing the effects of an absence of all functional UBE3A. Herein, we report the generation and functional characterization of a novel model of Angelman syndrome by deleting the entire Ube3a gene in the rat. We validated that this resulted in the first comprehensive gene deletion rodent model. Ultrasonic vocalizations from newborn Ube3a m−/p+ were reduced in the maternal inherited deletion group with no observable change in the Ube3a m+/p− paternal transmission cohort. We also discovered Ube3a m−/p+ exhibited delayed reflex development, motor deficits in rearing and fine motor skills, aberrant social communication, and impaired touchscreen learning and memory in young adults. These behavioral deficits were large in effect size and easily apparent in the larger rodent species. Low social communication was detected using a playback task that is unique to rats. Structural imaging illustrated decreased brain volume in Ube3a m−/p+ and a variety of intriguing neuroanatomical phenotypes while Ube3a m+/p− did not exhibit altered neuroanatomy. Our report identifies, for the first time, unique AS relevant functional phenotypes and anatomical markers as preclinical outcomes to test various strategies for gene and molecular therapies in AS.

UBE3A reinstatement as a disease‐modifying therapy for Angelman syndrome

Neuronal UBE3A substrates hold therapeutic potential for Angelman syndrome

[Angelman syndrome: current approach and the future of therapies]

Therapies in preclinical and clinical development for Angelman syndrome

Ube3a unsilencer for the potential treatment of Angelman syndrome

Adult Gene Therapy for Epilepsy in a Model of Angelman Syndrome: Hope or Hype?

UBE3A reinstatement restores behavior and proteome in an Angelman Syndrome mouse model of Imprinting Defects

Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model

An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript

Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA

Loss of nuclear UBE3A causes electrophysiological and behavioral deficits in mice and is associated with Angelman syndrome

Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome

Precision medicine in Angelman syndrome

Undiagnosed rare disease clinic identifies a novel UBE3A variant in two sisters with Angelman syndrome: The end of a diagnostic odyssey

A high-fidelity RNA-targeting Cas13 restores paternal Ube3a expression and improves motor functions in Angelman syndrome mice

Genetic investigation of the ubiquitin-protein ligase E3A gene as putative target in Angelman syndrome

Multiscale spatio-temporal dynamics of UBE3A gene in brain physiology and neurodevelopmental disorders

Translational outcomes in a full gene deletion of ubiquitin protein ligase E3A rat model of Angelman syndrome

Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a Expression in an Angelman Syndrome Mouse Brain

Angelman syndrome: a journey through the brain

Epilepsy-Associated UBE3A Deficiency Downregulates Retinoic Acid Signalling Pathway